Stock listing

BMV:AGIO Agios Pharmaceuticals, Inc. Acciones

Mexican listing (BMV) of Agios Pharmaceuticals, Inc. · home listing NASDAQ:AGIO

Follow Agios Pharmaceuticals, Inc. into a list and get an email when it puts out news.

Home listing price · NASDAQ:AGIO

$31.32 USD -1.00 (-3.1%)

Close on Oct 16, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:AGIO

Since Jul 6, 2026 -16.2% · daily closes, Jul 6, 2026 – Oct 16, 2026, adjusted for splits
Day range
$31.16 – $32.35 USDOct 16, 2026
Volume
952,660 sharesOct 16, 2026
Market value
$1.87B USDAt the close on Oct 16, 2026 · price × 59.70M shares outstanding
Agios Pharmaceuticals, Inc. logo
Ticker
BMV:AGIO
Asset type
Stock
Exchange
BMV
Currency
MXN

What changed lately

Calls

Replays

  • Agios Pharmaceuticals (NASDAQ:AGIO) Q2 2026 Earnings Call

    Thu, Jul 30, 2026 · 8:00 AM ET

    Watch Transcript

  • Agios Pharmaceuticals (NASDAQ:AGIO) Q1 2026 Earnings Call

    Wed, Apr 29, 2026 · 8:00 AM ET

    Watch Transcript

  • Agios Pharmaceuticals (NASDAQ:AGIO) Q4 2025 Earnings Call

    Thu, Feb 12, 2026 · 8:00 AM ET

    Watch Transcript

Latest news

Agios to Host Third Quarter 2026 Financial Results Conference Call and Webcast on November 5 at 8: 00 a.m. ET

Oct 8, 2026

Agios Reports Second Quarter 2026 Financial Results and Provides Business Update

Jul 30, 2026

Agios Provides Update on Phase 2 Trial of Tebapivat in Sickle Cell Disease

Jul 21, 2026

U.S. FDA Grants Priority Review to Agios’ sNDA for Mitapivat in Sickle Cell Disease

Jul 7, 2026

Agios to Host Second Quarter 2026 Financial Results Conference Call and Webcast on July 30 at 8: 00 a.m. ET

Jun 29, 2026

Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease

Jun 13, 2026

Agios Enters Exclusive Global License Agreement with Oscotec to Develop and Commercialize Next-Generation SYK Inhibitor Cevidoplenib

Jun 1, 2026

Agios Provides Update on Phase 2b Trial of Tebapivat in Lower-Risk Myelodysplastic Syndromes

May 29, 2026

Agios’ PYRUKYND® (mitapivat) Approved in the European Union for Adults with Thalassemia

May 22, 2026

Agios Submits sNDA to FDA for U.S. Accelerated Approval of Mitapivat in Sickle Cell Disease

May 12, 2026

All Agios Pharmaceuticals, Inc. news

Decks

Agios Pharmaceuticals, Inc. on 6ix

News releases
24 in the last 12 months · 217 in all · newest Oct 8, 2026 · oldest 2019
Calls
26 calls with a replay · 26 with a transcript · latest Jul 30, 2026
Decks
37 decks · latest Jul 30, 2026

Where Agios Pharmaceuticals, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:AGIO · Home listingNASDAQUnited StatesUSD
Lang & Schwarz:A1W2RMLang & SchwarzGermanyEUR
LS Exchange:A1W2RMLS ExchangeGermanyEUR
gettex:8APgettexGermanyEUR
LSE:0HB0LSEUnited KingdomUSD
BMV:AGIO · This pageBMVMexicoMXN
Tradegate:8APTradegateGermanyEUR
BOATS:AGIOBOATSUnited StatesUSD
BIVA:AGIOBIVAMexicoMXN
BX Swiss:8APBX SwissSwitzerlandCHF
Dusseldorf:8APDusseldorfGermanyEUR
Frankfurt:8APFrankfurtGermanyEUR
Munich:8APMunichGermanyEUR
Stuttgart:8APStuttgartGermanyEUR

Log in to ask 6ix AI your own questions about Agios Pharmaceuticals, Inc.